Navigation Links
Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference
Date:10/24/2007

- favorable pharmacokinetic and safety data observed in first clinical

trial of novel Fleximer(TM) anticancer agent -

CAMBRIDGE, Mass., Oct. 24 /PRNewswire/ -- Mersana, a cancer therapeutics company, announced interim results of a Phase I study of its lead product candidate, XMT-1001, in patients with advanced solid tumors. The data was presented by Edward A. Sausville, M.D., Ph.D, Professor of Medicine and Associate Director for Clinical Research, University of Maryland Greenebaum Cancer Center in a poster session on October 23 at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Therapeutics taking place in San Francisco, CA. Full text of the abstract #A146 "A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients with Advanced Solid Tumors" can be viewed online at the AACR website at http://www.aacr.org. XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity.

Commenting on the data, Robert J. Fram, M.D. Chief Medical Officer at Mersana, stated: "The Phase I results show that, in humans, camptothecin, the active agent in XMT-1001, is released gradually from the Fleximer carrier as a pro-drug in a manner that will potentially avoid common safety problems associated with drugs in this class. To date, we've seen no evidence of drug-related serious adverse events and the study is ongoing."

Results were presented from 12 patients enrolled in an ongoing Phase I open-label, dose-escalation trial designed to determine the safety, tolerability and pharmacokinetic profile of XMT-1001. To date, XMT-1001 has been well tolerated in patients and no serious drug related adverse events have been reported. Preliminary results demonstrate a favorable pharmacokinetic profile with low levels of CPT, both total and free, recovered in urine. The maximum tolerated dose (MTD) has not been reached and the study continues to accrue patients.

"Our Fleximer nanotechnology platform is designed to create proprietary new drugs from existing and novel pharmaceutical compounds," said Julie Olson, President and Chief Executive Officer of Mersana. "We are pleased to note that in the Phase I study, our proprietary Fleximer-controlled drug release system achieved results consistent with our objective of extending the half-life of the camptothecin analog while avoiding safety concerns. The favorable pharmacokinetic and safety data are consistent with results from preclinical studies of XMT-1001," she concluded.

About XMT-1001

XMT-1001 is Mersana's most advanced Fleximer(TM)-based product candidate. It utilizes a novel, dual release mechanism to liberate a camptothecin prodrug, which is then converted within cells into camptothecin, a DNA topoisomerase I inhibitor. In preclinical studies, XMT-1001 was better tolerated and more efficacious than either camptothecin or irinotecan in models of human cancer, showing extended plasma half-life and high concentrations in tumor tissue.

About Fleximer

Mersana is transforming oncology product development by creating new drugs from anti-cancer agents through application of its Fleximer nanotechnology platform. Fleximer is a novel, biodegradable and bio-inert polymer that can be chemically linked to drugs, including small chemical entities, peptides and biologics. Fleximer-based compounds can be individually designed to improve the therapeutic performance of drugs by modulating such properties as circulation time and site of release, while significantly improving toxicity profiles.

About Mersana Therapeutics, Inc.

Mersana, a privately held, venture backed company, utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. The key component of Mersana's platform is Fleximer(TM), a novel, biodegradable and bio-inert material that can be chemically linked to small molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer-camptothecin conjugate, which is currently in Phase 1 clinical trials and several preclinical stage oncology compounds. Mersana's investors include Fidelity Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech Ventures.

Fleximer is a trademark of Mersana Therapeutics, Inc.


'/>"/>
SOURCE Mersana Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... PAUL, Minn. , July 20, 2017  Prime Therapeutics ... Jonathan Gavras , M.D., following today,s Institute for Clinical ... report on the effectiveness and value of abuse-deterrent ... manager on the policy roundtable at the meeting. ... is not a material cost benefit to the use of ...
(Date:7/15/2017)... 2017 Enterin Inc., a Philadelphia ... (PD), today announced the completion of a $12.7 million Series ... III, as well as the participation of existing investors. ... have the support of New Ventures III and our current ... of the potential of our platform technology to transform the ...
(Date:7/13/2017)... 2017  Centurion Medical Products, a leader in medical product innovation ... impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of ... patient pain while preventing unneeded emergency department admission due to severe ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... 24, 2017 , ... Anyone who uses scales know they have limits; a ... using that same scale to dispense medication. The first example is an issue of ... why it is important to have the right balance for the process. METTLER TOLEDO’s ...
(Date:7/24/2017)... Calif. (PRWEB) , ... July 24, 2017 , ... A ... from food addiction to sexual abuse, and how she has overcome them. “Forbidden Memories: ... instances in her life and how she has risen above. , In “Memories,” readers ...
(Date:7/24/2017)... ... July 24, 2017 , ... Right now, behind ... The agency is hammering out a game plan to implement changes and compromises ... to affect FDA-regulated firms. The new law:, ,     Seeks ways ...
(Date:7/24/2017)... ... , ... “A Short Walk to the Mailbox”: a remarkable memoir of an ... author, Ed Clark. Ed Clark is a church music director and choral conductor. ... of music and worship leader for over fifty years. He has a master’s ...
(Date:7/23/2017)... (PRWEB) , ... July 23, 2017 , ... A ... in St. Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly ... of the disease offers very few benefits. , In the cases involved with ...
Breaking Medicine News(10 mins):